Mode
Text Size
Log in / Sign up

Adding dexmedetomidine to dexamethasone does not prolong analgesia in upper limb surgery

Adding dexmedetomidine to dexamethasone does not prolong analgesia in upper limb surgery
Photo by Pharmacy Images / Unsplash
Key Takeaway
Consider that adding dexmedetomidine to dexamethasone does not improve analgesia duration in upper limb surgery.

This randomized, placebo-controlled, triple-blind trial enrolled 100 patients undergoing upper limb surgery to evaluate whether adding i.v. dexmedetomidine 1 μg/kg to i.v. dexamethasone 0.15 mg/kg prolongs analgesia duration compared to dexamethasone alone. The primary outcome was duration of analgesia measured from block procedure to first oral opioid intake. The mean duration was 621 (334) minutes in the dexamethasone group and 690 (544) minutes in the dexamethasone-dexmedetomidine group, a difference that was not statistically significant (P=0.47). Secondary outcomes, including duration of sensory and motor blocks, pain scores, cumulative oral morphine consumption at 48 hours, and incidence of hypotension and bradycardia, also showed no significant differences between groups. Safety data were limited; serious adverse events and discontinuations were not reported. The study's limitations were not explicitly stated, but the small sample size and single-center design may affect generalizability. For clinicians, this evidence suggests that adding dexmedetomidine to dexamethasone does not provide a meaningful analgesic benefit in upper limb surgery, and routine use of this combination is not supported.

Study Details

Study typeRct
Sample sizen = 100
EvidenceLevel 2
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: Intravenous dexamethasone and dexmedetomidine are two adjuncts to local anaesthetics used independently to prolong analgesia after peripheral nerve block. This randomised, controlled, triple-blind trial tested the hypothesis that the combination of i.v. dexamethasone and dexmedetomidine would provide superior analgesia than i.v. dexamethasone alone as an adjunct in patients undergoing upper limb surgery with a supraclavicular brachial plexus block. METHODS: We randomised 100 participants to receive either dexamethasone 0.15 mg kg i.v. (Dexa group) or a combination of dexamethasone 0.15 mg kg and dexmedetomidine 1 μg kg i.v. (Dexa-Dexme group). The primary outcome was the duration of analgesia measured from the time of block procedure with a mix of mepivacaine 0.5% and ropivacaine 0.25% to first oral opioid intake. Secondary outcomes included duration of sensory and motor blocks, pain scores at rest and on movement, cumulative oral morphine consumption at 48 h, and incidence of hypotension episodes and bradycardia. RESULTS: The mean (sd) duration of analgesia was 621 (334) min in the Dexa group and 690 (544) min in the Dexa-Dexme group (P=0.47). Similarly, there were no significant differences in the secondary outcomes. CONCLUSIONS: The combination of i.v. dexamethasone and dexmedetomidine does not provide superior analgesia than i.v. dexamethasone alone after supraclavicular brachial plexus block. CLINICAL TRIAL REGISTRATION: NCT05389852.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.